Nebenwirkungen · NexoBrid
NexoBrid 5 g powder and gel for gel · Abschnitt 4.8 · PDF-Seite 9
HOS-213905 · Präparat HOS-155226
Local pain In pooled adults patients from studies MW2004, MW2005, MW2008 and MW2010 where preventive analgesia was practiced (as specified in section 4.2), pain related AEs were reported in 3.9% of -patients treated with this medicinal product vs. 3.5% of SOC-patients. In early studies before implementation of the preventive actions (Studies MW2001 and MW2002) including adult patients, where analgesia was provided on an on-demand basis, pain was reported in 23.4% of patients treated with this medicinal product and in 5.7% in the SOC group. In pooled paediatric population from studies MW2004, MW2008, and MW2012 (after implementation of preventive actions), pain was reported in (treated with this medicinal product vs. SOC): 7.9% vs. 9.3% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-03T16:44:00Z · SHA-256 0e966e92cc19adf0ef382cd0ae4ca84db51705148a696b737819286b20db4bab · Passage 760de4e68b6a3f1af7f1af572266a092abff1614ff8949d3bda6ce81b52c8991 · Zeichen 2920–3678 im Abschnitt